GoldenGolden
Agenus

Agenus

An immuno-oncology company developing treatments for cancer

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

December 1, 2020
Agenus launches phase 2 trial expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion.

Funding rounds

People

Name
Role
LinkedIn

Adam Hirsh

Employee

Alex Faylond

Employee

Bob Durham

Employee

Celena Toon

Employee

Christian Cortis

Employee

Christopher Clarke

Employee

Elben Guimaraes

Employee

Jacob Kung

Employee

Mike Klein

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
May 19, 2021
BioSpace
BMS inked a collaboration agreement with Exscientia that can leverage AI to speed the discovery of drug candidates in therapeutic areas, including oncology and immunology.
Mark Terry
May 18, 2021
BioSpace
Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
Ben Adams
May 18, 2021
FierceBiotech
Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact for two early-stage assets out of small biotech Agenus.
BioSpace
December 1, 2020
BioSpace
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the expansion of a Phase 2 trial into colon cancer based on a new objective clinical response in a colorectal cancer patient in addition to a significant tumor reduction of 27% and biomarker reduction observed i

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.